BTIG Reaffirms Their Buy Rating on Insulet (PODD)

BTIG analyst Marie Thibault reiterated a Buy rating on Insulet (PODDResearch Report) today and set a price target of $250.00. The company’s shares closed last Friday at $247.80.

According to TipRanks.com, Thibault is a 4-star analyst with an average return of 8.4% and a 34.2% success rate. Thibault covers the Healthcare sector, focusing on stocks such as Establishment Labs Holdings, Irhythm Technologies, and Edwards Lifesciences.

Insulet has an analyst consensus of Strong Buy, with a price target consensus of $272.63.

See Insiders’ Hot Stocks on TipRanks >>

The company has a one-year high of $324.81 and a one-year low of $181.00. Currently, Insulet has an average volume of 531.1K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Insulet Corp. is a medical device company. The firm engages in the development, manufacture and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Read More on PODD:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More